Isocarboxazid 与 Luvox CR
Isocarboxazid 与 Luvox CR互相作用以及同时服用的可能性。
在该服务的官方手册中,已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果,或起到良好效果。具体联合用药问题,需遵从医嘱。
用户:使用异卡波在一起,与沙明,不建议。 结合这些药物可以增加风险的一个罕见的,但严重的疾病叫做血清素综合症,其中可能包括的症状,如混乱、幻觉、扣押、极端变化血压,心率增加、发烧、多汗、颤抖或颤抖、视力模糊,肌肉痉挛或僵硬、震颤、不协调、胃痉挛、恶心、呕吐、腹泻。 严重的情况下可能导致昏迷甚至死亡。 在一般情况下,应至少等待14天之后,停止异卡波之前你开始处理与沙明. 相反,如果你最近一直在沙明,现在开始治疗异卡波,你应该检查你的医生或药剂师看到你多久之前应等待这是为你的安全使用异卡波,因为一些抗抑郁药可能需要一段时间才能明确自己的身体。 重要的是要告诉你的医生关于所有其他药物的使用,包括维生素和草药。 不停止使用任何药物,没有第一个说你的医生。
医界专家:禁:通过抑制血清素的新陈代谢,单胺氧化酶抑制剂(单胺氧化抑制剂)可以增强药物活动的有选择性的血清素再吸收抑制剂(Ssri)和增加风险的血清素综合症,这是一个罕见的,但是严重的和潜在的致命状况的思想导致过度刺激的脑干5-HT1A和2A受体。 症状的血清素综合征可以包括精神状态的变化,例如烦躁、改变的意识,混淆,幻觉和昏迷;自主神经功能障碍如性心动过速、热疗、发汗解表、颤抖、血压不稳定,并散瞳;神经肌肉异常比如反射亢进、肌阵挛、震颤、刚性,并共济失调;和胃肠道症状,例如腹部绞痛、恶心、呕吐、腹泻。
管理:在一般情况下,Ssri不应使用同时或单胺氧化抑制剂和其他药剂,拥有单胺氧化酶抑制剂的活动(例如,呋喃唑酮、丙卡巴肼). 至少14天应之间停止的单胺氧化酶抑制剂疗法和治疗开始与Ssri,反之亦然。 由于长期的一半生活中的氟西汀及其活动的代谢物,norfluoxetine,清除期5周的最低时,建议交换从氟西汀的一个单胺氧化酶抑制剂. 同样,清除期3周的时建议交换从vortioxetine到一种单胺氧化酶抑制剂.
- Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20
- Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4
- Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5
- Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
- "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
- Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
- Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
- Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2
- Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5
- Suchowersky O, deVries J "Possible interactions between deprenyl and prozac." Can J Neurol Sci 17 (1990): 352-3
- Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
- Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7
- Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1
- "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
- Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
- Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):
- Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1
- Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5
- "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.
- Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5
- Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822
- "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
- Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
- "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.
- Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5
- Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50
- Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
- Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5
- De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
- Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6
- "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
- Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
- Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
- "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
- Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552
在药物相容性与互相作用的检测过程中使用下列的信息来源:Drugs.com, Rxlist.com, Webmd.com, Medscape.com。
- Isocarboxazid-Luxiq
- Isocarboxazid-Lybrel
- Isocarboxazid-Lyderm
- Isocarboxazid-Lydia E. Pinkham
- Isocarboxazid-Lyme disease vaccine (recombinant ospa) Intramuscular
- Isocarboxazid-Lymepak
- Luvox CR-Isochron
- Luvox CR-IsoDitrate
- Luvox CR-Isoflurane
- Luvox CR-Isolyte H
- Luvox CR-Isolyte M in Dextrose
- Luvox CR-Isolyte P in Dextrose